Charles River Laboratories launches Rep/Cap plasmid
Share- Nishadil
- January 16, 2024
- 0 Comments
- 0.25 minutes read
- 37 Views
Charles River Laboratories ( NYSE: CRL ) said it has launched its off the shelf Rep/Cap plasmid offering, designed to streamline adeno associated virus based gene therapy programs. “The reduction in production time and improved efficacy of the supply chain will help accomplish our ultimate goal of delivering safe, effective therapies to patients, faster," said Kerstin Dolph, Senior Vice President, Manufacturing. More on Charles River Laboratories Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation Charles River: Q3 Points To Ongoing Deterioration
Disclaimer: This article was generated in part using artificial intelligence and may contain errors or omissions. The content is provided for informational purposes only and does not constitute professional advice. We makes no representations or warranties regarding its accuracy, completeness, or reliability. Readers are advised to verify the information independently before relying on
